Sosei Heptares Initiates to Reclaim Ownership GSK4381406 from GSK

Share this
Sosei Heptares


Sosei Heptares Initiates to Reclaim Ownership GSK4381406 from GSK


  • Sosei Heptares intends to regain full ownership of GSK4381406, an oral GPR35 agonist developed for Inflammatory Bowel Diseases (IBD) under a Global Collaboration and License Agreement
  • After GSK decides to deprioritize its development owing to changes in immunology research strategy, the company will recover full ownership of GSK4381406. Additionally as per the 2020 agreement, Sosei Heptares has the right, to reclaim ownership without upfront payment & GSK may receive a low single-digit royalty on net sales if commercial availability is reached
  • GSK4381406 developed by Sosei Heptares through its exclusive structure-based drug design (SBDD) platform & subsequently licensed to GSK in 2020

Ref: Finance Yahoo | Image: Sosei Heptares

Related News:- Sosei Heptares Receives $3.75M as a Part of its Multi-Target Agreement with Genentech

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions